Biotech: Page 24
-
Getty Images
FDA clears Roche breast cancer drug; Turnstone lays off 60% of staff
Itovebi is part of a push by Roche to make new inroads in breast cancer. Elsewhere, Turnstone is trimming preclinical research and Gritstone bio is working on a bankruptcy deal.
By BioPharma Dive staff • Oct. 11, 2024 -
Getty Images
Upstream prices $255M IPO in bid to challenge Amgen, AstraZeneca asthma drug
The offering will fund testing of a potential rival to Amgen’s Tezspire and is already the sixth for an immune drug developer this year, the most since 2021.
By Gwendolyn Wu • Oct. 10, 2024 -
Explore the Trendline➔
Spencer Platt via Getty Images
TrendlineEmerging biotech
New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.
By BioPharma Dive staff -
Getty Images
Purespring raises $105M to advance gene therapy for kidney disease
The Series B round will fund a Phase 1/2 trial of the company’s experimental treatment for IgA nephropathy.
By Delilah Alvarado • Oct. 9, 2024 -
Getty Images
Lilly partners with AI specialist Insitro to develop metabolic medicines
The latest deal in AI drug discovery is a twist on the usual big pharma-startup collaboration model, with Insitro licensing technology and Lilly eligible for royalties.
By Kristin Jensen • Oct. 9, 2024 -
Getty Images
Protein prediction wins chemistry Nobel; Alnylam submits an all-important drug application
AlphaFold’s developers were awarded science’s top prize. Elsewhere, J&J is shuttering an intriguing cancer study and Alnylam is asking for approval of a drug that could rival a Pfizer blockbuster.
By BioPharma Dive staff • Oct. 9, 2024 -
Permission granted by Basecamp Research
AI startup Basecamp allies with the Broad to dream up ‘programmable’ genetic medicines
The company, which is building a database of biological interactions found in nature, revealed $60 million in funding and a collaboration with David Liu’s lab.
By Gwendolyn Wu • Oct. 9, 2024 -
Permission granted by City Therapeutics
Startup led by John Maraganore raises $135M to build ‘future of RNAi’
“The time to re-enter the RNAi revolution is now,” said Robert Nelsen, the managing director of Arch, which led the Series A funding round for City Therapeutics.
By Ned Pagliarulo • Oct. 8, 2024 -
Permission granted by Intellia Therapeutics
Intellia starts late-stage test of CRISPR therapy for rare swelling disease
The study, of Intellia’s treatment for hereditary angioedema, is the second Phase 3 trial the biotech has begun testing its “in vivo” gene editing medicines.
By Ned Pagliarulo • Oct. 7, 2024 -
Permission granted by Judo Bio
Judo Bio debuts with $100M and a plan to take RNA drugs to the kidney
The Cambridge, Massachusetts-based biotech is using what it calls ligand-siRNA conjugates to reach drug targets in the kidney, which historically have been difficult to reach with RNA therapies.
By Gwendolyn Wu • Oct. 7, 2024 -
Courtesy of Editas Medicine
Editas trades Vertex fees for upfront cash in DRI deal
The gene editing company is selling to DRI Healthcare Trust future license fees that are owed to it under an agreement with Vertex last year.
By Delilah Alvarado • Oct. 4, 2024 -
Getty Images
Opdivo gets ‘perioperative’ approval; pharmas cut jobs in New Jersey, Ireland
Bristol Myers' immunotherapy can now be used before and after surgery in the U.S. Elsewhere, J&J, Bayer, Bristol Myers Squibb and Pfizer are trimming staff.
By BioPharma Dive staff • Oct. 4, 2024 -
Getty Images
An Alzheimer’s drugmaker is accused of data manipulation. Should its trials be stopped?
An experimental Alzheimer’s therapy from Cassava Sciences is still being tested in two Phase 3 studies, even as the company has come under scrutiny.
By Meagan Parrish • Updated Oct. 7, 2024 -
Getty Images
With $115M more, Triveni accelerates immune drug work
The biotech, which has now raised more than $200 million since launch, is advancing an eczema treatment that could start human trials next year.
By Gwendolyn Wu • Oct. 2, 2024 -
Retrieved from ASCO/Luke Franke 2024 on September 30, 2024
The top biopharma conferences remaining in 2025
Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies' research progress. Here’s a list of conferences to watch the rest of 2025.
By BioPharma Dive staff • Updated June 30, 2025 -
Getty Images
IGM lays off staff in autoimmune pivot; Metsera ramps up obesity drug supply
IGM is the latest biotech to focus on the potential for T cell engagers to treat inflammatory conditions. Elsewhere, Metsera signed a manufacturing deal and UCB started a first-of-its-kind trial.
By BioPharma Dive staff • Oct. 1, 2024 -
Getty Images
Kailera Therapeutics emerges from stealth with $400M for obesity drugs
The official launch comes five months after a filing indicated major investors such as Atlas Venture and Bain Capital were backing the biotech, then named “Hercules CM NewCo.”
By Gwendolyn Wu • Oct. 1, 2024 -
Getty Images
Aktis raises $175M to fuel radiopharma drug development
Among the investors in Aktis’ Series B round were Bristol Myers Squibb, Eli Lilly and Merck & Co., all of which have expanded their involvement in the radiopharma field.
By Delilah Alvarado • Sept. 30, 2024 -
Getty Images
J&J builds case for Talvey; FDA panel questions PD-1 drugs for certain cancers
New data show Talvey’s potential in multiple myeloma drug combinations. Elsewhere, AbbVie got more positive Parkinson’s drug data and Biogen ended a Sage collaboration.
By BioPharma Dive staff • Sept. 27, 2024 -
Getty Images
Approval in hand, Bristol Myers sets out to sell first-of-its-kind schizophrenia drug
While momentous, the approval of Cobenfy could also draw attention to an age-old problem in American healthcare: Will insurance barriers keep patients from getting an effective medicine?
By Jacob Bell • Updated Sept. 26, 2024 -
Getty Images
Arch raises another $3B biotech fund in pursuit of ‘coolest’ new science
Despite a restrictive funding climate, the startup creator is “in the ‘taking lots of risk’ mode,” said co-founder and managing director Robert Nelsen.
By Gwendolyn Wu • Sept. 26, 2024 -
Michael M. Santiago via Getty Images
BioAge prices $198M IPO, validating pivot to obesity drug research
The offering, which was upsized twice, will support development of a drug the company believes can boost the effects of popular weight loss medicines like Eli Lilly’s Zepbound.
By Gwendolyn Wu • Sept. 25, 2024 -
Getty Images
Metsera touts long-acting GLP-1 drug; Novartis strikes an AI deal
Metsera revealed Phase 1 data it claims could support a weight-loss medicine that's administered monthly. Elsewhere, Sanofi invested in a struggling biotech and shares of two Duchenne drug developers climbed.
By BioPharma Dive staff • Sept. 24, 2024 -
Permission granted by CRI
Q&AWant better cancer treatments? Make biopharma more like Silicon Valley
In an interview with PharmaVoice, Alicia Zhou, the new head of the nonprofit Cancer Research Institute, expressed a desire to foster deeper partnerships between scientists and the pharmaceutical industry.
By Michael Gibney • Sept. 24, 2024 -
Permission granted by Biogen
Biogen, UCB get the lupus data they’ve waited two decades for
The companies now plan on starting this year another large study of their medicine, dapirolizumab pegol, in the hopes that they can confirm its safety and effectiveness to drug regulators.
By Jacob Bell • Sept. 24, 2024 -
Courtesy of Biohaven Ltd.
After setback, Biohaven to seek approval of neurological disorder drug
With fresh, positive data in hand, Biohaven now believes its medicine could be the first to receive FDA approval for spinocerebellar ataxia.
By Jacob Bell • Sept. 23, 2024
Previous
